RPRX
Royalty Pharma plc38.38
-0.15-0.39%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
22.38BP/E (TTM)
21.93Basic EPS (TTM)
1.75Dividend Yield
0.02%Recent Filings
8-K
Royalty Pharma closes $2B notes
Royalty Pharma closed its $2 billion senior notes offering on September 16, 2025, issuing $600 million of 4.450% notes due 2031, $900 million of 5.200% notes due 2035, and $500 million of 5.950% notes due 2055, all guaranteed by key subsidiaries. Interest payments start March 25, 2026, on a semi-annual basis. The deal extends debt maturities while locking in fixed rates. Redemption options apply, but change of control triggers repurchase offers.
8-K
Fernandez steps down from board
Royalty Pharma's Lead Independent Director Henry Fernandez stepped down from the board on August 13, 2025, after five years of service since joining in July 2020, with no disagreements cited. His expertise as a public company CEO guided key milestones like the internalization, bolstering the firm's growth in biopharma royalties. The board expressed deep gratitude. A new Lead Independent Director will be named soon.
10-Q
Q2 FY2025 results
Royalty Pharma's Q2 FY2025 results showed total income and other revenues up 7.7% y/y to $578.7M, driven by 7.3% y/y growth in income from financial royalty assets to $550.4M, with Voranigo adding $39.2M in its first full quarter post-approval. Operating income dipped 22.2% y/y to $209.8M amid $300.5M R&D funding expense for daraxonrasib and litifilimab, yet provision income of $203.9M (derived) from higher Evrysdi and Xtandi forecasts offset prior-year expense. Portfolio Receipts surged 19.7% y/y to $727.5M, fueled by cystic fibrosis franchise and Trelegy gains, while free cash flow stood at $960.1M after $351.0M capex-equivalent R&D outlays. The May 2025 internalization closed for $565.2M (cash/equity per Note 3), recognizing $924.6M goodwill with no finite-lived intangibles disclosed; total debt rose to $8.0B including a $380M term loan (due 2027 at SOFR+1.60%), with $1.8B revolver availability and covenant compliance. Cash ended at $631.9M. Sales risks from biopharmaceutical products linger, as noted in Risk Factors.
8-K
Q2 Receipts up 20%
Royalty Pharma reported Q2 2025 Portfolio Receipts surging 20% to $727 million, fueled by strong royalties from Voranigo, Trelegy, Evrysdi, and Tremfya, while Royalty Receipts climbed 11% to $672 million. The company closed its acquisition of external manager RP Management in May 2025, integrating operations and slashing future costs, and inked a $2 billion funding deal with Revolution Medicines, including a $1.25 billion synthetic royalty on daraxonrasib. It repurchased $1 billion in shares year-to-date. Raised 2025 guidance to $3.05-$3.15 billion, signaling robust pipeline momentum. Integration boosts efficiency.
8-K
Board adds biopharma, finance experts
Royalty Pharma appointed Carole Ho, Chief Medical Officer at Denali Therapeutics, and Elizabeth Weatherman, Special Limited Partner at Warburg Pincus, to its Board of Directors effective July 17, 2025. Both independent directors bring deep biopharma and finance expertise, boosting independent representation above 90% amid enhanced governance post-external manager acquisition. Their insights sharpen strategy execution. No family ties or special arrangements disclosed.
IPO
Sector
Industry
BLRX
BioLineRx Ltd.
3.01-0.17
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CPMD
Cannapharmarx Inc.
0.00-0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
RGBP
Regen Biopharma, Inc.
0.01-0.00
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
VOXR
Vox Royalty Corp.
5.04-0.29
XOMA
XOMA Royalty Corporation
25.83+0.34